Endometrial Preparation for Frozen-Thawed Embryo Transfer With or Without Pretreatment With GnRH Agonist: A Randomized Controlled Trial at Two Centers.

Plain-language guide to PMID 34733238 (2021): randomized controlled trial of Gonadorelin in 133 patients, endometriosis.

Key Facts

PMID: 34733238
Journal: Frontiers in endocrinology
Year: 2021
Study type: Randomized Controlled Trial
Authors: Xu J et al. (6 authors)
DOI: 10.3389/fendo.2021.722253

What This Study Did, in Plain Language

What Was Tested

This randomized controlled trial looks at Gonadorelin in the context of endometriosis.

This prospective randomized controlled trial compared the reproductive outcomes of frozen embryo transfer (FET) with hormone replacement treatment (HRT) with or without gonadotropin-releasing hormone agonist (GnRHa) pretreatment.

Why It Was Studied

The study was registered with the Chinese Clinical Trial Registry (ChiCTR-IOR-17014170; http://www.chictr.org.cn).

Who Took Part

The abstract describes 133 patients taking part.

PubMed indexes the participants as adults, both men and women.

A total of 133 patients scheduled for HRT-FET mainly because of tubal and/or male factors who received two high-quality cleavage-stage embryos were enrolled at two participating centers.

The GnRHa group (n = 65) received GnRHa pretreatment, while the control group (n = 68) did not.

How the Study Was Run

In design terms this was a randomized study.

Random assignment meant chance, not the researchers, decided who got Gonadorelin and who got the comparison, which limits bias.

Analysis was based on the intention-to-treat (ITT) principle.

What Was Measured

PubMed files the paper under topics including Birth Rate, Blastocyst, Cryopreservation, Embryo Implantation, Embryo Transfer, Endometrium and Fertility Agents, Female.

The authors tagged it with the keywords GnRH agonist, endometrial preparation, frozen embryo transfer, hormone replacement treatment and reproductive outcomes.

What This Means in Plain Language

The paper is a randomized study of Gonadorelin in 133 patients in people with endometriosis.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2021 (Frontiers in endocrinology), a journal based in Switzerland.

More context: the Gonadorelin compound page, Endometriosis research.

Our Notes on the Compound

Gonadorelin: A synthetic version of gonadotropin-releasing hormone (GnRH), the signal that tells the pituitary to release LH and FSH.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.